Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Preclinical development of a bispecific antibody that safely and effectively targets CD19 and CD47 for the treatment of B cell lymphoma and leukemia.

Buatois V, Johnson Z, Salgado-Pires S, Papaïoannou A, Hatterer E, Chauchet X, Richard F, Barba L, Daubeuf B, Cons L, Broyer L, D'Asaro M, Matthes T, LeGallou S, Fest T, Tarte K, Clarke Hinojosa RK, Genescà Ferrer E, Ribera JM, Dey A, Bailey K, Fielding AK, Eissenberg L, Ritchey J, Rettig M, DiPersio JF, Kosco-Vilbois MH, Masternak K, Fischer N, Shang L, Ferlin WG.

Mol Cancer Ther. 2018 May 9. pii: molcanther.1095.2017. doi: 10.1158/1535-7163.MCT-17-1095. [Epub ahead of print]

PMID:
29743205
2.

Poly-functional and long-lasting anticancer immune response elicited by a safe attenuated Pseudomonas aeruginosa vector for antigens delivery.

Chauchet X, Hannani D, Djebali S, Laurin D, Polack B, Marvel J, Buffat L, Toussaint B, Le Gouëllec A.

Mol Ther Oncolytics. 2016 Dec 14;3:16033. doi: 10.1038/mto.2016.33. eCollection 2016.

3.

Triggering the apoptosis of targeted human renal cancer cells by the vibration of anisotropic magnetic particles attached to the cell membrane.

Leulmi S, Chauchet X, Morcrette M, Ortiz G, Joisten H, Sabon P, Livache T, Hou Y, Carrière M, Lequien S, Dieny B.

Nanoscale. 2015 Oct 14;7(38):15904-14. doi: 10.1039/c5nr03518j. Epub 2015 Sep 14.

PMID:
26364870
4.

Cellular and molecular mechanisms activating the cell death processes by chalcones: Critical structural effects.

Champelovier P, Chauchet X, Hazane-Puch F, Vergnaud S, Garrel C, Laporte F, Boutonnat J, Boumendjel A.

Toxicol In Vitro. 2013 Dec;27(8):2305-15. doi: 10.1016/j.tiv.2013.09.021. Epub 2013 Oct 14.

PMID:
24134853
5.

Live-attenuated bacteria as a cancer vaccine vector.

Toussaint B, Chauchet X, Wang Y, Polack B, Le Gouëllec A.

Expert Rev Vaccines. 2013 Oct;12(10):1139-54. doi: 10.1586/14760584.2013.836914. Review.

PMID:
24124876
6.

A safe bacterial microsyringe for in vivo antigen delivery and immunotherapy.

Le Gouëllec A, Chauchet X, Laurin D, Aspord C, Verove J, Wang Y, Genestet C, Trocme C, Ahmadi M, Martin S, Broisat A, Cretin F, Ghezzi C, Polack B, Plumas J, Toussaint B.

Mol Ther. 2013 May;21(5):1076-86. doi: 10.1038/mt.2013.41. Epub 2013 Mar 26.

7.

Bacterial vectors for active immunotherapy reach clinical and industrial stages.

Le Gouëllec A, Chauchet X, Polack B, Buffat L, Toussaint B.

Hum Vaccin Immunother. 2012 Oct;8(10):1454-8. doi: 10.4161/hv.21429. Epub 2012 Aug 16. Review.

Supplemental Content

Loading ...
Support Center